Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
05/2013
05/16/2013WO2013071093A1 Pyrazine compounds useful as inhibitors of atr kinase
05/16/2013WO2013071085A1 Pyrazine compounds useful as inhibitors of atr kinase
05/16/2013WO2013070660A1 Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
05/16/2013WO2013070620A1 Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase
05/16/2013WO2013069771A1 Anthranilic acid derivative and noxious organism control agent
05/16/2013WO2013069765A1 Nitrogenated heterocyclic compound
05/16/2013WO2013069762A1 Cyclic azine compound having nitrogen-containing fused aromatic group, method for producing same, and organic electroluminescent element using same as constituent component
05/16/2013WO2013069721A1 Metal complex, and adsorbent, absorbent and separator formed of same
05/16/2013WO2013069297A1 7-{(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal
05/16/2013WO2013068875A1 2-thiopyrimidinones
05/16/2013WO2013068769A1 Pharmaceutical compounds
05/16/2013WO2013068755A1 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
05/16/2013WO2013068489A1 Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a
05/16/2013WO2013068470A1 Inhibitors of phosphodiesterase type 10a
05/16/2013WO2013067578A1 Modulators of c3a receptors
05/16/2013US20130123504 Pharmacologically active compounds containing sulfur
05/16/2013US20130123500 Ethinyl-pyrazole derivative
05/16/2013US20130123494 Complex compound and optical recording medium containing same
05/16/2013US20130123493 Process for the synthesis of substituted urea compounds
05/16/2013US20130123302 Process for the preparation of 2-(cyclohexylmethyl)-n--1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
05/16/2013US20130123299 Compounds and methods for treatment of systemic lupus erythematosus
05/16/2013US20130123289 Certain amino-pyrimidines, compositions thereof, and methods for their use
05/16/2013US20130123284 Heterocyclic compounds useful for kinase inhibition
05/16/2013US20130123281 Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules
05/16/2013US20130123275 Pyrazine derivatives
05/16/2013US20130123271 Heterocyclic compounds, their preparation and therapeutic application
05/16/2013US20130123270 Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
05/16/2013US20130123267 1-pyridazinyl-hydroxyimino-3-phenyl-propanes
05/16/2013US20130123265 Compounds that modulate intracellular calcium
05/16/2013US20130123260 Methods
05/16/2013US20130123258 4(1H)-Quinolones Having Antimalarial Activity With Reduced Chemical Resistance
05/16/2013US20130123257 Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
05/16/2013US20130123247 Arthropodicidal anthranilamides
05/16/2013US20130123244 Hetero-Bicyclic Derivatives as HCV Inhibitors
05/16/2013US20130123243 Diamine derivatives as inhibitors of leukotriene a4 hydrolase
05/16/2013US20130123241 Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
05/16/2013US20130123239 Compounds having trpv1 antagonistic activity and uses thereof
05/16/2013US20130123234 Aryl- or Heteroaryl-Substituted Benzene Compounds
05/16/2013US20130123232 Azetidinyl diamides as monoacylglycerol lipase inhibitors
05/16/2013US20130123230 2-Thiopyrimidinones
05/16/2013US20130123229 CB1 Receptor Antagonists and Uses Thereof
05/16/2013US20130123215 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (fprl-1) receptor modulators
05/16/2013US20130121963 N-phenyl-2-pyrimidineamine derivatives
05/16/2013US20130119359 Organic Electroluminescent Element, Material for Organic Electroluminescent Element, and Light Emitting Device, Display Device and Illumination Device Each Using the Element
05/16/2013CA2855390A1 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (fprl-1) receptor modulators
05/16/2013CA2855204A1 Pharmaceutical compounds
05/16/2013CA2855022A1 7-{(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal
05/16/2013CA2854836A1 Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
05/16/2013CA2854329A1 Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase
05/16/2013CA2853024A1 2-thiopyrimidinones
05/16/2013CA2852820A1 Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a
05/16/2013CA2852604A1 Inhibitors of phosphodiesterase type 10a
05/16/2013CA2849566A1 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
05/15/2013EP2592905A1 Compound, charge transporting material and organic electroluminescent element
05/15/2013EP2592154A1 Immobilization products and methods for the identification of histone demethylase interacting molecules and for the purification of histone demethylase proteins
05/15/2013EP2592076A1 Substituted pyridine compound
05/15/2013EP2592075A1 Pyridazine compounds for the treatment of inflammatory diseases
05/15/2013EP2592070A2 Tetrazole-substituted arylamides
05/15/2013EP2591674A1 Heterocyclic compounds as pest controllers
05/15/2013EP2591673A1 Pest control agent
05/15/2013EP2590964A1 Anthranilic acid diamide derivative as a pesticide
05/15/2013EP2590963A1 (3 -methylpyrrolidin- 3 - yl) methyl pyridinyl ether derivatives and their use as nk-3 receptor antagonists
05/15/2013EP2590962A2 Process of preparing a thrombin specific inhibitor
05/15/2013EP2590961A1 Piperidinyl pyrimidine amides as kv7 potassium channel openers
05/15/2013EP2590960A1 Heterocyclic antiviral compounds
05/15/2013EP2590957A2 Chemical compounds
05/15/2013EP2590953A1 Tetrazole compounds as calcium channel blockers
05/15/2013EP2590951A1 Benzenesulfonamides useful as sodium channel inhibitors
05/15/2013EP2590950A1 N-cyclyl-3 - (cyclylcarbonylaminomethyl) benzamide derivatives as rho kinase inhibitors
05/15/2013EP2590947A1 Intermediates and process for preparing a thrombin specific inhibitor
05/15/2013EP2590946A1 Bipyridyl derivatives useful for the treatment of kinase - induced diseases
05/15/2013EP2590944A1 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
05/15/2013EP2590942A1 Rho kinase inhibitors
05/15/2013EP2590655A1 Compounds and methods for inhibiting phosphate transport
05/15/2013EP2590647A2 Pro-neurogenic compounds
05/15/2013CN103108872A Process for the preparation of 5-substituted 1-alkyltetrazolyl oxime derivatives
05/15/2013CN103108871A 17a-hydroxylase/c17,20-lyase inhibitors
05/15/2013CN103108866A Cyclohexane derivative compound
05/15/2013CN103108548A Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders
05/15/2013CN103102352A Tyrosine kinase inhibitor indolinone derivative
05/15/2013CN103102344A Aminoquinazoline derivative, salts thereof and application method
05/15/2013CN103102343A Preparation method of rupatadine fumarate
05/15/2013CN103102342A Aminoquinazoline derivative, salts thereof and application method
05/15/2013CN103102341A Preparation method of balofloxacin dihydrate
05/15/2013CN103102340A Preparation method of nicotine
05/15/2013CN103102303A Benzylamine derivatives as CETP inhibitors
05/15/2013CN102076671B Triazole derivative or salt thereof
05/15/2013CN101808994B Compounds and methods for kinase modulation, and indications therefor
05/15/2013CN101687848B Solid state forms of racemic ilaprazole
05/15/2013CN101648943B Method for preparing (S)-omeprazole in subject and object after inclusion and resolution by separation
05/14/2013US8440837 2-substituted-ethynylthiazole derivatives and uses of same
05/14/2013US8440823 Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
05/14/2013US8440701 Trisubstituted 1,2,4 triazoles
05/14/2013US8440682 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors
05/14/2013US8440675 Potentiator of radiation therapy
05/14/2013US8440673 Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists
05/14/2013US8440672 Diphenyl substituted alkanes
05/14/2013US8440665 Apoptosis signal-regulating kinase inhibitors
05/14/2013US8440663 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use
05/14/2013US8440653 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists
1 ... 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 ... 1080